Cash Flow Statement (Annual)

CVSI / CV Sciences, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss -46 -2,300 -1,312 -12,233 -14,141 -4,897
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization - - 934 1,012 1,053 183
    Amortization Of Financing Costs - - 0 265 289 220
    Amortization Of Debt Discount Premium 0 211 589 - - -
    Issuance Of Stock And Warrants For Services Or Claims - - 0 328 541 0
    Share Based Compensation - 0 7,916 5,720 2,733 3,420
    Royalty Buyout - - - - - -
    Provision For Doubtful Accounts 0 400 -300 2,655 59 483
    Increase Decrease In Interest Payable Net - - - 0 128 189
    Derivative Gain Loss On Derivative Net - - - 0 147 249
  Increase Decrease In Operating Capital
    Increase Decrease In Accounts Receivable 0 1,744 -1,206 588 -70 1,241
    Increase Decrease In Notes Receivable Current - - - - 0 25
    Increase Decrease In Inventories 0 2,128 9,193 2,468 -1,309 -1,043
    Increase Decrease In Prepaid Deferred Expense And Other Assets 0 474 -1,215 -520 -61 401
    Increase Decrease In Accounts Payable And Accrued Liabilities - - - 531 -355 1,780
    Increase Decrease In Deferred Revenue And Customer Advances And Deposits - - - - 0 981
    Net Cash Provided By Used In Operating Activities -64 - - - -2,054 3,615
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment 0 227 449 114 17 455
  Payments For Leasing Costs Commissions And Tenant Improvements - - - - - -
  Net Cash Provided By Used In Investing Activities - - - - 853 -2,000
Net Cash Provided By Used In Financing Activities
  Proceeds From Convertible Debt - - 0 1,508 1,975 750
  Repayments Of Convertible Debt - - - 0 612 0
  Repayments Of Notes Payable - 100 92 39 174 159
  Proceeds From Stock Options Exercised - - - - - -
  Net Cash Provided By Used In Financing Activities 63 - - - 1,740 119
  Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect - - - - - -
  Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - -
Noncash Investing And Financing Items
  Stock Issued During Period Value Conversion Of Convertible Securities - - 6,000 778 583 1,805
  Value Of Embedded Derivative At Inception - - - 0 370 29
  Issuance Of Common Stock In Consideration For Royalty Buyout - - - - - -
  Issuance Of Common Stock To Settle Restricted Stock Units - - - - 0 0
  Issuance Of Common Stock For Prepaid Expenses And Other Current Assets - - - - - -
  Stock Redeemed Or Called During Period Value - - - - - 75
Supplemental Cash Flow Information
  Interest Paid Net - - - - 338 183
  Income Taxes Paid 0 0 0 0 22 44

Peers - Cannabis and Medical Marijuana Dispensaries (512227)

Related Articles

REPH: Recro Pharma Analysis and Research Report

12h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

13h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

13h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 126654102